Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
Adenocarcinoma
/ genetics
Aged
Biomarkers, Tumor
/ genetics
Carcinoma, Squamous Cell
/ genetics
Case-Control Studies
Female
Follow-Up Studies
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Prognosis
Survival Rate
Tumor Microenvironment
/ immunology
Uterine Cervical Neoplasms
/ genetics
KEGG
TCGA
bioinformatics analysis
cervical cancer
tumor immune
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Feb 2021
28 Feb 2021
Historique:
received:
03
02
2021
revised:
22
02
2021
accepted:
24
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
13
5
2021
Statut:
epublish
Résumé
Cervical cancer is primarily caused by the infection of high-risk human papillomavirus (hrHPV). Moreover, tumor immune microenvironment plays a significant role in the tumorigenesis of cervical cancer. Therefore, it is necessary to comprehensively identify predictive biomarkers from immunogenomics associated with cervical cancer prognosis. The Cancer Genome Atlas (TCGA) public database has stored abundant sequencing or microarray data, and clinical data, offering a feasible and reliable approach for this study. In the present study, gene profile and clinical data were downloaded from TCGA, and the Immunology Database and Analysis Portal (ImmPort) database. Wilcoxon-test was used to compare the difference in gene expression. Univariate analysis was adopted to identify immune-related genes (IRGs) and transcription factors (TFs) correlated with survival. A prognostic prediction model was established by multivariate cox analysis. The regulatory network was constructed and visualized by correlation analysis and Cytoscape, respectively. Gene functional enrichment analysis was performed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). A total of 204 differentially expressed IRGs were identified, and 22 of them were significantly associated with the survival of cervical cancer. These 22 IRGs were actively involved in the JAK-STAT pathway. A prognostic model based on 10 IRGs (
Identifiants
pubmed: 33671013
pii: ijms22052442
doi: 10.3390/ijms22052442
pmc: PMC7957482
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : China Scholarship Council
ID : Qun Wang
Références
Curr Opin Obstet Gynecol. 2019 Oct;31(5):333-339
pubmed: 30946033
Oncotarget. 2018 Jul 17;9(55):30594-30609
pubmed: 30093972
Int Immunopharmacol. 2019 Apr;69:279-288
pubmed: 30743204
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Mol Cancer. 2010 Oct 14;9:273
pubmed: 20946648
J Exp Clin Cancer Res. 2010 Jun 18;29:78
pubmed: 20565840
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Oncol Res. 2018 Jul 5;26(6):977-985
pubmed: 28893346
Immunol Res. 2014 May;58(2-3):234-9
pubmed: 24791905
Biochemistry (Mosc). 2012 Aug;77(8):934-40
pubmed: 22860916
Front Genet. 2020 Oct 14;11:533628
pubmed: 33173530
Cancer. 2007 Oct 15;110(8):1738-44
pubmed: 17786947
Int J Gynecol Cancer. 2017 May;27(4):634-642
pubmed: 28338494
FASEB Bioadv. 2020 Jun 30;2(7):398-408
pubmed: 32676580
J Int Med Res. 2019 Mar;47(3):1330-1338
pubmed: 30700181
Cancer Res. 2015 Jun 1;75(11):2211-21
pubmed: 25855377
DNA Cell Biol. 2020 Feb;39(2):255-272
pubmed: 31977248
Int J Clin Exp Pathol. 2015 Aug 01;8(8):8717-30
pubmed: 26464616
Pathol Oncol Res. 2008 Dec;14(4):365-71
pubmed: 18543080
Cytotherapy. 2018 Mar;20(3):385-393
pubmed: 29331266
Br J Cancer. 2009 Sep 15;101(6):967-72
pubmed: 19638983
J Cell Physiol. 2020 Feb;235(2):993-1000
pubmed: 31332778
Gynecol Oncol. 2007 Jan;104(1):181-5
pubmed: 16996116
BMC Cancer. 2020 Nov 23;20(1):1133
pubmed: 33228592
JAMA Oncol. 2017 Nov 1;3(11):1529-1537
pubmed: 28687838
Arch Gynecol Obstet. 2017 Mar;295(3):705-712
pubmed: 28013346
Mol Ther Oncolytics. 2019 Sep 24;15:108-116
pubmed: 31709304
Asian Pac J Cancer Prev. 2015;16(17):7401-7
pubmed: 26625735
J Immunol. 2011 Aug 1;187(3):1157-65
pubmed: 21709158
Jpn J Clin Oncol. 2021 Feb 8;51(2):167-172
pubmed: 33244581
Anticancer Agents Med Chem. 2014 Feb;14(2):190-203
pubmed: 24237223
Front Oncol. 2020 Dec 17;10:557280
pubmed: 33392068
J Recept Signal Transduct Res. 2010 Jun;30(3):178-88
pubmed: 20415542
Mol Cell Biochem. 2009 Oct;330(1-2):193-9
pubmed: 19421717
Cell Mol Immunol. 2015 Nov;12(6):743-9
pubmed: 25531392
Aging (Albany NY). 2019 Jan 20;11(2):480-500
pubmed: 30661062
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1051-9
pubmed: 18217980
World J Surg Oncol. 2017 Sep 18;15(1):173
pubmed: 28923073
Obstet Gynecol Sci. 2019 May;62(3):157-165
pubmed: 31139591
Gynecol Oncol. 2009 Jan;112(1):248-56
pubmed: 19007971
Onco Targets Ther. 2019 Jul 26;12:5823-5833
pubmed: 31440058
Sci Rep. 2017 Nov 28;7(1):16495
pubmed: 29184082
Int J Cancer. 2014 Jan 15;134(2):437-44
pubmed: 23824834
FEBS Open Bio. 2020 Dec;10(12):2750-2760
pubmed: 33098235
J Ovarian Res. 2020 Nov 7;13(1):131
pubmed: 33160404
Int J Cancer. 2009 Oct 15;125(8):1851-8
pubmed: 19585495
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1546-53
pubmed: 20338481
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Virol. 2021 Feb 24;95(6):
pubmed: 33361419
Strahlenther Onkol. 2017 Dec;193(12):1048-1055
pubmed: 28660291
Stem Cells Int. 2018 Apr 2;2018:1241323
pubmed: 29760719
J Pathol. 2009 Oct;219(2):222-31
pubmed: 19644956
IET Syst Biol. 2020 Dec;14(6):314-322
pubmed: 33399095
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287